Palvella Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Palvella Therapeutics, Inc. (PVLA) had Deferred Tax Assets, Operating Loss Carryforwards of $91.96 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $91.96M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $81.97M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $9.18M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $67.50M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $54.84M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $91.96M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $81.97M 10-K · filed 2026-03-31 | |
| 2023-12-31 | $9.18M 10-K · filed 2025-03-31 | $67.50M 10-K · filed 2024-03-29 |
| 2022-12-31 | $54.84M 10-K · filed 2024-03-29 | |
| 2021-12-31 | $49.28M 10-K · filed 2023-03-31 | |
| 2020-12-31 | $39.17M 10-K · filed 2022-03-02 | |
| 2019-12-31 | $30.45M 10-K · filed 2021-03-31 | |
| 2018-12-31 | $27.88M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $22.17M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $18.50M 10-K · filed 2018-03-15 | $18.50M 10-K · filed 2017-03-30 |
| 2015-12-31 | $13.05M 10-K · filed 2017-03-30 | $4.15M 10-K · filed 2016-03-23 |
| 2014-12-31 | $9.95M 10-K · filed 2016-03-23 | |
| 2014-06-30 | $5.43K 10-Q · filed 2014-12-12 | |
| 2013-12-31 | $16.86M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |